Ernest Solvay award for Hannah Walgrave

Hannah Walgrave, PhD student at the De Strooper lab (VIB-KU Leuven) received the Ernest Solvay Prize 2022 from the Queen Elisabeth Medical Foundation for her research on the role of adult neurogenesis in Alzheimer’s disease.

Congratulations, Hannah!

Can you tell us what adult neurogenesis is exactly, and how it affects Alzheimer’s disease?

“Adult neurogenesis is the process of generating new neurons that integrate into existing circuits after normal development. We know that people with Alzheimer's disease produce fewer new brain cells throughout their lives compared to people of the same age who do not suffer from dementia. However, the production of new brain cells can be stimulated by an active lifestyle and learning new things, so if we can understand the regulation of neurogenesis in detail, we might be able to harness this knowledge and come up with new treatments.”

How did you tackle this in your PhD research?

“We found a micro-RNA (miRNA-132) that can stimulate the production of new brain cells in mouse models of Alzheimer's disease. The levels of miRNA-132 are much lower in the brains of people with Alzheimer’s disease though, so we tested whether we could address this in our Alzheimer’s disease animal models by supplementing this particular miRNA. We saw that indeed, the production of new brain cells increased, and what’s more, that this could improve cognitive function.”

That sounds exciting!

“Yes it does, and I believe the Queen Elisabeth Medical Foundation is also excited. Currently, we are investigating how miRNA-132 exerts its effects and whether we can translate this approach to an actual therapeutic strategy for patients. What I love about our approach is that we try to harness the brain’s innate potential to regenerate lost cells and tissues—perhaps indeed the solution will be found within this remarkable organ.”

Hannah Walgrave

Hannah Walgrave

PhD student, De Strooper lab

 

Share

Latest stories

Website preview
MRM Health – Redefining Microbiome Therapeutics
In a world increasingly driven by precision medicine and natural, safer therapies, MRM Health is pioneering a new frontier: using live bacterial therapeutics to improve human health. Spun out of the VIB ecosystem and built on decades of microbiome research, the company is leading a transformative shift in how chronic inflammatory diseases are treated by targeting the gut microbiome – a complex, vital ecosystem often regarded as a separate organ due to its pivotal role in overall health.
blog.vib.be
Website preview
Cracking the ALS Genetic Code: Insights from VIB Researchers
Learn about major findings in the decoding of ALS from SOD1 to C9orf72 and their implications for future therapies, as highlighted in The Lancet Neurology review series. Join us in celebrating this ALS Awareness Day.
blog.vib.be
Website preview
VIB-UAntwerp Center for Molecular Neurology expands focus
Under the joint leadership of Rosa Rademakers and Renzo Mancuso, the Center is expanding its pioneering work in neurogenetics into neuroimmunology.
blog.vib.be

About VIB Blog

On our blog, you can find content curated by the VIB community. Discover our research through the eyes of our scientists.

Want to be kept up-to-date on our biotechnological news and stories? Join our community and subscribe to our bi-monthly newsletter here.

Contact

Suzanne Tassierstraat 1 9052 Ghent

communications@vib.be

vib.be